Benzylidene ketal derivatives as M2 muscarinic receptor antagonists.

被引：0

作者：

Boyle, CD ^{[1
]}

Chackalamannil, S ^{[1
]}

Chen, LY ^{[1
]}

Dugar, S ^{[1
]}

Pushpavanam, P ^{[1
]}

Billard, W ^{[1
]}

Binch, H ^{[1
]}

Crosby, G ^{[1
]}

Coffin, VL ^{[1
]}

Cohen-Williams, M ^{[1
]}

Duffy, RA ^{[1
]}

Ruperto, V ^{[1
]}

Taylor, LA ^{[1
]}

McQuade, RD ^{[1
]}

Lachowicz, JE ^{[1
]}

机构：

[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2000年 / 220卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

114-MEDI

引用

页码：U556 / U556

页数：1

共 50 条

[1] Benzylidene ketal derivatives as M2 muscarinic receptor antagonists
Boyle, CD
Chackalamannil, S
Chen, LY
Dugar, S
Pushpavanam, P
Billard, W
Binch, H
Crosby, G
Cohen-Williams, M
Coffin, VL
Duffy, RA
Ruperto, V
Lachowicz, JE
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (24) : 2727 - 2730
[2] Metabolic stabilization of benzylidene ketal M2 muscarinic receptor antagonists via halonaphthoic acid substitution
Boyle, CD
Chackalamannil, S
Clader, JW
Greenlee, WJ
Josien, HB
Kaminski, JJ
Kozlowski, JA
McCombie, SW
Nazareno, DV
Tagat, JR
Wang, YG
Zhou, GW
Billard, W
Binch, H
Crosby, G
Cohen-Williams, M
Coffin, VL
Cox, KA
Grotz, DE
Duffy, RA
Ruperto, V
Lachowicz, JE
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (17) : 2311 - 2314
[3] Orally active and selective benzylidene Ketal M2 muscarinic receptor antagonists for the treatment of Alzheimer's disease
Boyle, CD
Lachowicz, JE
DRUG DEVELOPMENT RESEARCH, 2002, 56 (03) : 310 - 320
[4] Pharmacokinetic improvement of benzylidene ketal M2 muscarinic receptor antagonists via aryl amide modification.
Boyle, CD
Vice, SF
Chackalamannil, S
Clader, JW
Ford, J
Greenlee, WJ
Josien, HB
McCombie, SW
Nazareno, DV
Tagat, JR
Wang, YG
Billard, W
Binch, H
Crosby, G
Cohen-Williams, M
Coffin, VL
Cox, KA
Grotz, DE
Duffy, RA
Ruperto, V
Lachowicz, JE
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U641 - U641
[5] Novel 2-benzyl-piperidine derivatives as selective M2 muscarinic receptor antagonists.
Zhao, SH
Berger, J
Miller, AK
Flippin, L
Clark, R
Maag, H
Stepane, G
Watson, N
Shetty, SG
Cefalu, JS
Dawson, MW
Rocha, C
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U200 - U200
[6] Enhancement of pharmacokinetic properties and in vivo efficacy of benzylidene ketal M2 muscarinic receptor antagonists via benzamide modification
Boyle, CD
Vice, SF
Campion, J
Chackalamannil, S
Lankin, CM
McCombie, SW
Billard, W
Binch, H
Crosby, G
Williams, MC
Coffin, VL
Cox, KA
Grotz, DE
Duffy, RA
Ruperto, V
Lachowicz, JE
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (23) : 3479 - 3482
[7] Potent M2 muscarinic receptor antagonists
Barrett, D
Barlocco, D
DRUG DISCOVERY TODAY, 2001, 6 (05) : 268 - 268
[8] Isopropyl amide derivatives of potent and selective muscarinic M2 receptor antagonists
Palani, A
Dugar, S
Clader, JW
Greenlee, WJ
Ruperto, V
Duffy, RA
Lachowicz, JE
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (07) : 1791 - 1794
[9] Synthesis of new cardioselective M2 muscarinic receptor antagonists
Mandelli, GR
Maiorana, S
Terni, P
Lamperti, G
Colibretti, ML
Imbimbo, BP
CHEMICAL & PHARMACEUTICAL BULLETIN, 2000, 48 (11) : 1611 - 1622
[10] Diphenyl sulfoxides as selective antagonists of the muscarinic M2 receptor
Kozlowski, JA
Lowe, DB
Guzik, HS
Zhou, GW
Ruperto, VB
Duffy, RA
McQuade, R
Crosby, G
Taylor, LA
Billard, W
Binch, H
Lachowicz, JE
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (20) : 2255 - 2257

← 1 2 3 4 5 →